Litcius/Paper detail

In Vitro Selection of Macrocyclic α/β<sup>3</sup>-Peptides against Human EGFR

Risa Wakabayashi, Marina Kawai, Takayuki Katoh, Hiroaki Suga

2022Journal of the American Chemical Society15 citationsDOIOpen Access PDF

Abstract

Here, we report ribosomal construction of thioether-macrocyclic α/β3-peptide libraries in which β-homoglycine, β-homoalanine, β-homophenylglycine, and β-homoglutamine are introduced by genetic code reprogramming. The libraries were applied to the RaPID (Random nonstandard Peptides Integrated Discovery) selection against human EGFR to obtain PPI (protein–protein interaction) inhibitors. The resulting peptides contained up to five β3-amino acid (β3AA) residues and exhibited outstanding binding affinity, PPI inhibitory activity, and proteolytic stability, which were attributed to the β3AAs included in the peptides. This showcase work has demonstrated that the use of such β3AAs enhances the drug-like properties of peptides, providing a unique platform for the discovery of de novo macrocycles against a protein of interest.

Topics & Concepts

ChemistryThioetherPeptideIn vitroCombinatorial chemistryBiochemistryAmino acidDrug discoveryComputational biologyPeptide libraryDNAPeptide sequenceStereochemistryBiologyGeneChemical Synthesis and AnalysisRNA and protein synthesis mechanismsMonoclonal and Polyclonal Antibodies Research
In Vitro Selection of Macrocyclic α/β<sup>3</sup>-Peptides against Human EGFR | Litcius